Page last updated: 2024-08-16

thalidomide and cc-292

thalidomide has been researched along with cc-292 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Beà, S; Campo, E; Colomer, D; Giné, E; Lee, E; Lopez-Guerra, M; López-Guillermo, A; Matas-Cespedes, A; Navarro, A; Pérez-Galán, P; Rivas-Delgado, A; Rodriguez, V; Roué, G; Vidal-Crespo, A	1

Other Studies

1 other study(ies) available for thalidomide and cc-292

Article	Year
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status. Haematologica, 2017, Volume: 102, Issue:11 Topics: Acrylamides; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thalidomide	2017

Article

Year

The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status.

Haematologica, 2017, Volume: 102, Issue:11

Topics: Acrylamides; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Mutation; NF-kappa B; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thalidomide

2017